PURPOSE: To determine the impact of longer periods between biopsy-confirmed breast cancer diagnosis and the initiation of treatment (Dx2Tx) on survival. PATIENTS AND METHODS: This study was a noninterventional, retrospective analysis of adult female North Carolina Medicaid enrollees diagnosed with breast cancer from January 1, 2000, through December, 31, 2002, in the linked North Carolina Central Cancer Registry-Medicaid Claims database. Follow-up data were available through July 31, 2006. Cox proportional hazards regression models were constructed to evaluate the impact on survival of delaying treatment ≥ 60 days after a confirmed diagnosis of breast cancer. RESULTS: The study cohort consisted of 1,786 low-income, adult women with a mean age of 61.6 years. A large proportion of the patients (44.3%) were racial minorities. Median time from biopsy-confirmed diagnosis to treatment initiation was 22 days. Adjusted Cox proportional hazards regression showed that although Dx2Tx length did not affect survival among those diagnosed at early stage, among late-stage patients, intervals between diagnosis and first treatment ≥ 60 days were associated with significantly worse overall survival (hazard ratio [HR], 1.66; 95% CI, 1.00 to 2.77; P = .05) and breast cancer-specific survival (HR, 1.85; 95% CI, 1.04 to 3.27; P = .04). CONCLUSION: One in 10 women waited ≥ 60 days to initiate treatment after a diagnosis of breast cancer. Waiting ≥ 60 days to initiate treatment was associated with a significant 66% and 85% increased risk of overall and breast cancer-related death, respectively, among late-stage patients. Interventions designed to increase the timeliness of receiving breast cancer treatments should target late-stage patients, and clinicians should strive to promptly triage and initiate treatment for patients diagnosed at late stage.
PURPOSE: To determine the impact of longer periods between biopsy-confirmed breast cancer diagnosis and the initiation of treatment (Dx2Tx) on survival. PATIENTS AND METHODS: This study was a noninterventional, retrospective analysis of adult female North Carolina Medicaid enrollees diagnosed with breast cancer from January 1, 2000, through December, 31, 2002, in the linked North Carolina Central Cancer Registry-Medicaid Claims database. Follow-up data were available through July 31, 2006. Cox proportional hazards regression models were constructed to evaluate the impact on survival of delaying treatment ≥ 60 days after a confirmed diagnosis of breast cancer. RESULTS: The study cohort consisted of 1,786 low-income, adult women with a mean age of 61.6 years. A large proportion of the patients (44.3%) were racial minorities. Median time from biopsy-confirmed diagnosis to treatment initiation was 22 days. Adjusted Cox proportional hazards regression showed that although Dx2Tx length did not affect survival among those diagnosed at early stage, among late-stage patients, intervals between diagnosis and first treatment ≥ 60 days were associated with significantly worse overall survival (hazard ratio [HR], 1.66; 95% CI, 1.00 to 2.77; P = .05) and breast cancer-specific survival (HR, 1.85; 95% CI, 1.04 to 3.27; P = .04). CONCLUSION: One in 10 women waited ≥ 60 days to initiate treatment after a diagnosis of breast cancer. Waiting ≥ 60 days to initiate treatment was associated with a significant 66% and 85% increased risk of overall and breast cancer-related death, respectively, among late-stage patients. Interventions designed to increase the timeliness of receiving breast cancer treatments should target late-stage patients, and clinicians should strive to promptly triage and initiate treatment for patients diagnosed at late stage.
Authors: Karin Gwyn; Melissa L Bondy; Deborah S Cohen; Mary Jo Lund; Jonathan M Liff; Elaine W Flagg; Louise A Brinton; J William Eley; Ralph J Coates Journal: Cancer Date: 2004-04-15 Impact factor: 6.860
Authors: Tracy A Battaglia; Julie S Darnell; Naomi Ko; Fred Snyder; Electra D Paskett; Kristen J Wells; Elizabeth M Whitley; Jennifer J Griggs; Anand Karnad; Heather Young; Victoria Warren-Mears; Melissa A Simon; Elizabeth Calhoun Journal: Breast Cancer Res Treat Date: 2016-07-18 Impact factor: 4.872
Authors: Amit G Singal; Akbar K Waljee; Nishant Patel; Emerson Y Chen; Jasmin A Tiro; Jorge A Marrero; Adam C Yopp Journal: J Natl Compr Canc Netw Date: 2013-09-01 Impact factor: 11.908
Authors: Christopher J Louis; Jonathan R Clark; Marianne M Hillemeier; Fabian Camacho; Nengliang Yao; Roger T Anderson Journal: J Rural Health Date: 2017-01-19 Impact factor: 4.333
Authors: Angela K Green; Emeline M Aviki; Konstantina Matsoukas; Sujata Patil; Deborah Korenstein; Victoria Blinder Journal: Breast Cancer Res Treat Date: 2018-08-09 Impact factor: 4.872
Authors: Alok Kapoor; Tracy A Battaglia; Alexis P Isabelle; Amresh D Hanchate; Richard L Kalish; Sharon Bak; Rebecca G Mishuris; Swati M Shroff; Karen M Freund Journal: J Health Care Poor Underserved Date: 2014-02
Authors: Ali Johnson; Leanne Shulman; Jennifer Kachajian; Brian L Sprague; Farrah Khan; Ted James; David Cranmer; Peter Young; Ruth Heimann Journal: J Oncol Pract Date: 2016-08-30 Impact factor: 3.840
Authors: Karen M Freund; Tracy A Battaglia; Elizabeth Calhoun; Julie S Darnell; Donald J Dudley; Kevin Fiscella; Martha L Hare; Nancy LaVerda; Ji-Hyun Lee; Paul Levine; David M Murray; Steven R Patierno; Peter C Raich; Richard G Roetzheim; Melissa Simon; Frederick R Snyder; Victoria Warren-Mears; Elizabeth M Whitley; Paul Winters; Gregory S Young; Electra D Paskett Journal: J Natl Cancer Inst Date: 2014-06-17 Impact factor: 13.506
Authors: Mariana Chavez-MacGregor; Christina A Clarke; Daphne Y Lichtensztajn; Sharon H Giordano Journal: JAMA Oncol Date: 2016-03 Impact factor: 31.777
Authors: Richard J Bleicher; Karen Ruth; Elin R Sigurdson; J Robert Beck; Eric Ross; Yu-Ning Wong; Sameer A Patel; Marcia Boraas; Eric I Chang; Neal S Topham; Brian L Egleston Journal: JAMA Oncol Date: 2016-03 Impact factor: 31.777